Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 5Head & Neck 5Gastrointestinal 3Sarcoma 2Gynecologic 2Genitourinary 2Dermatologic 2CNS 1Breast 1

Conditions

Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Ovarian Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Adjuvants, Pharmaceutic × Gynecologic × Clear all
NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Marker Therapeutics, Inc.

Phase 2 Terminated
120 enrolled 12 charts
Gynecologic

Ovarian Neoplasms

NCT02576561 2017-10-25

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

THEVAX Genetics Vaccine

Phase 2 Unknown
10 enrolled
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡